Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 9 August 2024, including: Amgen, Inc. positions for obesity and diabetes; Bristol Myers Squibb Company returns TIGIT asset in pipeline reshuffle; is Kerendia the next jewel in Bayer AG’s crown?; Japan pharma firms cut jobs; and Sun Pharmaceutical Industries Ltd. seeks GLP-1 partner.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Amgen Gets Into Position For MariTide Development" - Scrip, 6 August, 2024.)
(Also see "BMS Returns TIGIT Bispecific To Agenus Amid Pipeline Reshuffle" - Scrip, 5 August, 2024.)
(Also see "Kerendia Could Be Next Jewel In Bayer's Pharma Crown" - Scrip, 6 August, 2024.)
(Also see "Japan Pharma Layoffs: Takeda And Others Implementing Broad Cuts" - Scrip, 8 August, 2024.)
(Also see "Sun Seeks Partner For GLP-I Asset, Legal Challenge Clouds Alopecia Drug Launch" - Scrip, 5 August, 2024.)
